Rankings / Mood, Anxiety & Stress

Xanomeline-trospium (KarXT / Cobenfy)

Mood, Anxiety & Stress · M1/M4 muscarinic agonist + peripheral antagonist

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

cholinergicprescription
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Xanomeline-trospium (KarXT / Cobenfy) as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

Bristol Myers Squibb (acquired Karuna 2024).

Studied, labeled, or reported-use context: FDA label: 50/20 mg twice daily with titration up to 125/30 mg twice daily — Rx; not individualized guidance.

What the evidence says

Bristol Myers Squibb (acquired Karuna 2024). First fundamentally new schizophrenia mechanism since clozapine (1989). Avoids dopamine D2 blockade entirely — sidesteps weight gain, EPS, prolactin elevation, and tardive dyskinesia. Active investigation in Alzheimer's psychosis, ADHD, BPD. Major clinical advance even though efficacy is comparable to atypicals.

Mechanism

Combination drug: xanomeline is a centrally acting M1/M4 muscarinic acetylcholine receptor agonist (developed in 1990s but shelved due to peripheral cholinergic side effects); trospium is a peripherally restricted muscarinic antagonist that blocks the GI/cardiac side effects without crossing the BBB — allowing the central effect to be tolerated; first novel mechanism for schizophrenia in 50+ years

Studied, labeled, or reported dose & route

FDA label: 50/20 mg twice daily with titration up to 125/30 mg twice daily

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Xanomeline-trospium (KarXT / Cobenfy)'s effects?
Read Off Label rates the evidence for Xanomeline-trospium (KarXT / Cobenfy) as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). Bristol Myers Squibb (acquired Karuna 2024).
What safety findings are reported for Xanomeline-trospium (KarXT / Cobenfy)?
Xanomeline-trospium (KarXT / Cobenfy) has a med risk profile in the database. Med (nausea, vomiting, dyspepsia, constipation, hypertension; the M1/M4 mechanism avoids the metabolic syndrome and EPS of D2-blocker antipsychotics) Legal status: Rx (FDA-approved Sept 2024 for schizophrenia).
What doses or routes are reported for Xanomeline-trospium (KarXT / Cobenfy)?
FDA label: 50/20 mg twice daily with titration up to 125/30 mg twice daily This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Xanomeline-trospium (KarXT / Cobenfy) work?
Combination drug: xanomeline is a centrally acting M1/M4 muscarinic acetylcholine receptor agonist (developed in 1990s but shelved due to peripheral cholinergic side effects); trospium is a peripherally restricted muscarinic antagonist that blocks the GI/cardiac side effects without crossing the BBB — allowing the central effect to be tolerated; first novel mechanism for schizophrenia in 50+ years

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.